<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02512796</url>
  </required_header>
  <id_info>
    <org_study_id>18302</org_study_id>
    <nct_id>NCT02512796</nct_id>
  </id_info>
  <brief_title>In Vitro Study of the Effect of Gadolinium Contrast on Fibrocytes</brief_title>
  <official_title>In Vitro Study of the Effect of Gadolinium Contrast on Fibrocytes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gadolinium contrast agents are frequently administered for MRI imaging. Very little is known&#xD;
      of its toxicity outside of patients with reduced renal function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gadolinium contrast is administered to patients during MRI imaging. Recently, the&#xD;
      investigators have observed potential gadolinium toxicity in some patients. To investigate&#xD;
      this, the investigators propose to collect clinical data and lab data obtained as a part of&#xD;
      clinical care. The investigators also plan to obtain 25 cc of peripheral blood at 2-4 weeks,&#xD;
      4-6 weeks and again at 3 months to identify unique monocyte signatures, gene polymorphisms,&#xD;
      and to quantitate circulating fibrocytes (in fresh blood and after culture). Plan to enroll&#xD;
      15 patients with kidney, pancreas or liver transplant and exposed to gadolinium contrast&#xD;
      agents, 15 non-transplant patients exposed to gadolinium contrast and 30 age- and sex-matched&#xD;
      healthy controls not exposed to gadolinium contrast.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>total number of circulating fibrocytes</measure>
    <time_frame>2-4 weeks</time_frame>
    <description>2-4 weeks after gadolinium contrast exposure</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Gadolinium Toxicity</condition>
  <arm_group>
    <arm_group_label>Transplant patients, MRI with Gadolinium contrast dye</arm_group_label>
    <description>Patients with kidney, pancreas or liver transplant and exposed to gadolinium contrast agents.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-transplant patients, MRI with Gadolinium contrast dye</arm_group_label>
    <description>Non-transplant patients exposed to gadolinium contrast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls, no transplant no Gadolinium contrast dye</arm_group_label>
    <description>Age- and sex-matched healthy controls not exposed to gadolinium contrast.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadolinium contrast dye</intervention_name>
    <description>Gadolinium contrast dye administered during MRI</description>
    <arm_group_label>Non-transplant patients, MRI with Gadolinium contrast dye</arm_group_label>
    <arm_group_label>Transplant patients, MRI with Gadolinium contrast dye</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Investigators plan to study the circulating fibrocytes numbers, changes in monocyte gene&#xD;
      transcripts, identify polymorphism in gadolinium transport genes (OATPB1/3 and MRP2) and&#xD;
      examine their osteogenic potential in cultures.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Gadolinium exposed patients. We will use age- and sex-matched controls with and without&#xD;
        organ transplants and not exposed to gadolinium contrast agents (within the last 3 years)&#xD;
        as controls.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Renal, pancreas or liver transplant OR those without organ transplant OR controls&#xD;
&#xD;
          -  Age 18-70&#xD;
&#xD;
          -  Both gender&#xD;
&#xD;
          -  Exposure to gadolinium contrast agents (no exposure in controls)&#xD;
&#xD;
          -  Have had a transplant, have had a contrast dye with an MRI&#xD;
&#xD;
          -  Have not had a transplant and have had a contrast dye with an MRI&#xD;
&#xD;
          -  Healthy person who has not had an MRI or gadolinium for any other reason.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  End stage kidney disease or Stage 5&#xD;
&#xD;
          -  Previous diagnosis of Nephrogenic Systemic Fibrosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sundararaman Swaminathan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sundararaman Swaminathan, MD</last_name>
    <phone>434-982-3577</phone>
    <email>ss4sa@virginia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>July 27, 2015</study_first_submitted>
  <study_first_submitted_qc>July 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2015</study_first_posted>
  <last_update_submitted>July 30, 2015</last_update_submitted>
  <last_update_submitted_qc>July 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver transplantation</keyword>
  <keyword>Renal transplantation</keyword>
  <keyword>Pancreas transplantation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

